Elocalcitol

DB06194ExperimentalSmall molecule

Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).

Mechanism: Pharmacologically active on Vitamin D3 receptor
Curator reviewed
Primary indication: Investigated for use/treatment in benign prostatic hyperplasia, urinary incontinence, prostate disorders, and infertility.Curator reviewed
Formula / weight: C₂₉H₄₃FO₂ · 442.6489 g/mol (avg)
Code names: BXL-628 · RO-26-9228

Resolves to

Compound

UNII2WDS5F2V6QCAS199798-84-0PubChem11396600

Structure

InChIKeyLRLWXBHFPGSUOX-GJQYOBCGSA-NSMILESCCC(O)(CC)\C=C\C[C@H](C)C1=CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@@](F)([H])C1=C

Targets

P11473VDR

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

156Drug interactionsStructured to mechanism, not free text

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elocalcitol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account